Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Latest filing published 12 May 2025 for Nautilus Biotechnology, Inc., €7,829. Read the official filing
Filing timeline
BuySaleParag Mallick
Insider track record
Disclosed buys
1
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-22.3%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
No signal scores available.
Parag Mallick: trading record in brief
All filings by Parag Mallick on record concern Nautilus Biotechnology, Inc., in the capacity of chief executive. We count 2 filings; the first trade dates from 21 December 2021 and the latest from 8 May 2025.
Every open-market trade on record is a purchase: 1 purchase worth €7,829, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2025: 1 purchase and no sales on the market.
On 12 May 2025 came the latest disclosure, an open-market purchase for €7,829 in Nautilus Biotechnology, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Parag Mallick
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
12,000 shares@ US$0.7323100.0% of flowCommon StockSEC:0001808805-25-000049:0
Canonical exit: 6 Aug 2025 (T+90)
210,000 shares0Common StockSEC:0001808805-21-000031:0
2 of 2 declarations
